Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.
See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.
Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.
Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.
Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.
TITLE/ COMPANY | Issue Date | Status | Details |
---|---|---|---|
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed. Dr. Reddy's Laboratories Limited Formulations Technical Operations, FTO-11 |
18 Jul 2025 | Normal | Justification: The observations highlight persistent CAPA issues not adequately preventing recurring problems. Excerpt: CAPA was focused only on the probable root cause for failure, but preventive actions were not adequate. View Details |
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed. Apothecary Pharma LLC |
15 May 2025 | Normal | Justification: CAPA processes are crucial as the SOP for it is not finalized, impacting issue resolution mechanisms. Excerpt: Failed to finalize SOP1011 Corrective Action/ Preventative Action (CAPA). View Details |
Procedures for corrective and preventive action have not been adequately established. Aurolige Pharma LLC |
10 Apr 2025 | Normal | Justification: CAPA's role in identifying root causes and implementing solutions is crucial, as highlighted by repeated complaints. Excerpt: Investigation report... failed to mention... previous investigations... potential root cause... View Details |
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed Aurolige Pharma LLC |
10 Apr 2025 | Normal | Justification: CAPAs performed but failed to prevent future occurrences indicating inadequate plan execution. Excerpt: CAPA was completed and approved...did not support microbial growth. View Details |
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess. Zhejiang Huahai Pharmaceutical Co., Ltd. |
24 Jan 2025 | Normal | Justification: Effective CAPA efforts require controlled adjustments with appropriate review to maintain product quality. Excerpt: Operators have the ability to change the values for reject limits for each batch and to make changes during the batch. View Details |
View and learn more about FDA Inspections
with our comprehensive list of resources